文献速递类风湿关节炎

Nipocalimab联合certolizumab治疗活动性类风湿关节炎的2a期DAISY-RA研究

Nipocalimab and certolizumab combination therapy in participants with active rheumatoid arthritis despite prior treatment with advanced therapies: results from the phase 2a DAISY-RA study.
PubMed 文献 · RMD Open · 2026-03-04

这项2a期研究将103例既往先进治疗失败的活动性类风湿关节炎患者按3:2随机分配至nipocalimab联合certolizumab组或certolizumab单药组。第12周主要终点DAS28-CRP变化两组相似,联合组严重不良事件报告率高于单药组。联合治疗中nipocalimab呈现非线性药代动力学并显著可逆性降低血清IgG包括ACPA水平。

要点

  • 联合治疗与单药治疗第12周DAS28-CRP变化相似,主要终点无显著差异
  • 联合组严重不良事件报告率11.3%,高于单药组2.4%
  • nipocalimab联合certolizumab时清除加速并显著可逆性降低血清IgG

核心结论

  • 在活动性类风湿关节炎患者中,nipocalimab联合certolizumab治疗在第12周主要终点和次要终点上与certolizumab单药治疗相似。

研究设计与样本

  • 2a期研究,103例既往接受先进治疗后仍患活动性类风湿关节炎的参与者按3:2随机分配至联合治疗组(n=62)或单药治疗组(n=41)。
  • 联合组接受nipocalimab静脉30 mg/kg联合certolizumab皮下400 mg(第0、2、4周)后200 mg,每2周一次至第24周;单药组接受certolizumab单药每2周一次至第24周。
  • 主要终点为第12周DAS28-CRP较基线的变化,其他结局评估至第30周。

主要发现

  • 第12周主要终点两组相似:联合组最小二乘均值90%CI为-1.92(-2.48至-1.36),单药组为-1.86(-2.44至-1.28),p=0.822。
  • 第12周达到ACR50、DAS28-CRP<2.6和DAS28-CRP≤3.2的参与者比例联合组数值上高于单药组,但次要终点总体相似。
  • 严重不良事件报告率联合组为11.3%,单药组为2.4%。
  • nipocalimab联合certolizumab时呈现非线性药代动力学,清除加速,并显著、可逆性降低血清免疫球蛋白G,包括抗瓜氨酸化蛋白抗体水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the efficacy, safety, pharmacokinetics, immunogenicity and pharmacodynamics of combination therapy with nipocalimab and certolizumab in participants with active rheumatoid arthritis (RA) despite treatment with advanced therapies. METHODS: In this phase 2a study, participants were randomised 3:2 to receive combination therapy with nipocalimab (intravenous 30 mg/kg) and certolizumab (subcutaneous 400 mg at weeks 0, 2, 4, then 200 mg) or certolizumab monotherapy every 2 weeks from weeks 0 to 24. The primary endpoint was change from baseline in Disease Activity Score 28 using C-reactive protein (DAS28-CRP) at week 12. Other outcomes were assessed through week 30. RESULTS: 103 participants were enrolled (combination therapy/monotherapy, n=62/41). At week 12, the primary endpoint was similar between groups (least squares mean 90% CI -1.92 (-2.48 to -1.36) vs -1.86 (-2.44 to -1.28); p=0.822). Secondary endpoints were also similar between groups, although numerically higher proportions of participants treated with combination therapy versus monotherapy achieved ≥50% response in American College of Rheumatology criteria (ACR50), DAS28-CRP <2.6 and DAS28-CRP ≤3.2 at week 12. Serious adverse events were reported in 11.3% of participants in the combination therapy group and 2.4% in the monotherapy group. In combination with certolizumab, nipocalimab exhibited nonlinear pharmacokinetics with accelerated clearance and substantially, reversibly reduced serum immunoglobulin G, including anticitrullinated protein antibody levels. CONCLUSIONS: Combination therapy of nipocalimab with certolizumab showed a similar outcome in the primary endpoint and secondary endpoints compared with certolizumab monotherapy in participants with active RA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Taylor PC, Schett G, Huizinga TWJ, et al. Nipocalimab and certolizumab combination therapy in participants with active rheumatoid arthritis despite prior treatment with advanced therapies: results from the phase 2a DAISY-RA study. RMD Open. 2026. PMID: 41781163. doi:10.1136/rmdopen-2025-006464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。